TrueMRD TOMBOLA Trial
Muscle-Invasive Bladder Cancer (MRD-guided therapy)
Phase 2Long term follow-up
Key Facts
Indication
Muscle-Invasive Bladder Cancer (MRD-guided therapy)
Phase
Phase 2
Status
Long term follow-up
Company
About Veracyte
Veracyte is a commercial-stage genomic diagnostics leader with a mission to improve patient care through molecular insights at critical cancer decision points. The company has achieved significant scale, having served over 800,000 patients, and its tests are widely adopted and embedded in major clinical guidelines. Its core strategy revolves around the Veracyte Diagnostics Platform, a proprietary data-generation engine that uses whole-ome profiling and AI to continuously discover new biomarkers, expand test utility, and build robust clinical evidence, fueling both commercial growth and pipeline expansion into areas like minimal residual disease (MRD) detection.
View full company profile